Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)

• Conditions: Central Nervous System Lymphoma

• Registration Number: NCT03859544
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma (DLBCL) entity with a particularly poor prognosis (median survival less than 3 years). They are still poorly characterized biologically, largely because of their rarity (300 cases / year in France) and the difficulty for obtaining a material of sufficient quality and quantity. It is nevertheless assumed that their pathophysiology is particular, since they develop exclusively in an immunological sanctuary, and that they present some characteristic molecular abnormalities (mutation of MYD88 or TBL1XR1 for example).

A collection of 74 PCNSLs has created, clinically annotated, from which frozen material is available in addition to the material fixed and included in paraffin (cohort ALYCE). Informed consent was gathered for all patients. Comparative Genomic Hybridization-array analysis of this cohort has already revealed abnormalities associated with a poor prognosis (unpublished data). The objective of this study is to complete this analysis by sequencing a panel of 96 mutant genes recurrently in DLBCLs and PCNSLs, and the molecular determination of the original cell by the (RT-MLPA) Reverse Transcriptase-Multiplex Ligation-dependent Probe Amplification technique.

The integration of genetic, molecular and transcriptomic data may define prognostic markers and open perspectives for translational research in PCNSL.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-01
• Status Verified: 2019-02
• Study First Submitted: 2019-02-28
• Study First Submitted QC: 2019-02-28
• Last Update Submitted: 2019-02-28
• Study First Posted: 2019-03-01
• Last Update Posted: 2019-03-01
• Primary Completion: 2020-01-01
• Study Completion: 2020-01-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• Adults
• With a lymphoma of the central nervous system
• Patients having signed the consent for the conservation of their samples within the cohort

Read More

Exclusion Criteria

• <18 old years
• Other diagnosis than lymphoma of the central nervous system
• No consent form signed

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression free survival	Up to 48 months	Analysis of progression-free survival correlated with genomic data and mutation data

Trial Locations

Locations (1)

Service d'hématologie biologique - Centre Hospitalier Lyon Sud - HCL; 🇫🇷 Pierre-Bénite, France